Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
04-08-01 Tiagabine
| Tiagabine |
|
Formulary
|
Tablets 5mg, 10mg, 15mg Epilepsy. Only to be considered in line with NICE as a third line add-on treatment option in people with focal seizures. |
 MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products MHRA: Antiepileptics: risk of suicidal thoughts and behaviour |
|
Links
- DVLA: Epilepsy and driving fact sheet
- FDA: Drug Safety Communication - Risk of Serious Skin Reactions (Mar13)
LSCMMG: Position Statement Levetiracetam (Keppra) prescribing: bioequivalence and antiepileptic drugs- MHRA Drug Safety Update April 2018: Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met
- MHRA Drug SAfety Update April 2018: Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met
- MHRA Drug Safety Update April 2018: Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met
- MHRA Drug Safety Update April 2018: Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met
- MHRA Drug Safety Update April 2018: Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met
- MHRA Drug Safety Update April 2019: Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April
- MHRA Drug Safety Update April 2019: Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme
- MHRA Drug Safety Update Aril 2022: Pregabalin (Lyrica): findings of safety study on risks during pregnancy
- MHRA Drug Safety Update Feb 2016: Valproate and of risk of abnormal pregnancy outcomes: new communication materials
- MHRA Drug Safety Update Feb 2021: Pregabalin (Lyrica): reports of severe respiratory depression
- MHRA Drug Safety Update Jan 2021: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA Drug Safety Update July 2022: Topiramate (Topamax): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure
- MHRA Drug Safety Update May 2018: https://www.gov.uk/drug-safety-update/valproate-medicines-epilim-depakote-pregnancy-prevention-programme-materials-online
- MHRA Drug Safety Update May 2018: Valproate medicines (Epilim, Depakote): Pregnancy Prevention Programme materials online
- MHRA Drug Safety Update May 2018: Valproate medicines (Epilim, Depakote): Pregnancy Prevention Programme materials online
- MHRA Drug Safety Update May 2018: Valproate medicines (Epilim, Depakote): Pregnancy Prevention Programme materials online
- MHRA Drug Safety Update Nov 2017: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA Drug Safety Update Oct 2017: Gabapentin (Neurontin): risk of severe respiratory depression
- MHRA Drug Safety Update September 2018: Valproate medicines (Epilim, Depakote): Pregnancy Prevention Programme materials online
- MHRA Drug Safety Update September 2018: Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers
- MHRA Drug Safety Update September 2018: Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers
- MHRA Drug Safety Update September 2018: Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers
- MHRA Drug Safety Update: Valproate and of risk of abnormal pregnancy outcomes: new communication materials
- MHRA Drug Safety Update: Valproate and of risk of abnormal pregnancy outcomes: new communication materials
- MHRA Drug Safety Update: Valproate and of risk of abnormal pregnancy outcomes: new communication materials
- MHRA safety update on pigmentation July 2013
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression
- MHRA: Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions
- MHRA: Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions
- MHRA: Gabapentin (Neurontin): risk of severe respiratory depression
- MHRA: Phenytoin: risk of Stevens-Johnson syndrome associated with HLA-B*1502 allele in patients of Thai or Han Chinese ethnic origin
- MHRA: Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April
- MHRA: Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April
- MHRA: Pregabalin (Lyrica): findings of safety study on risks during pregnancy
- MHRA: Pregabalin (Lyrica): reports of severe respiratory depression
- MHRA: Retigabine (Trobalt▼): indication restricted to last-line use and new monitoring requirements
- MHRA: Topiramate (Topamax): introduction of new safety measures, including a Pregnancy Prevention Programme
- MHRA: Topiramate (Topamax): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure
- MHRA: Valproate use in men: as a precaution, men and their partners should use effective contraception
- MHRA: Valproate use in men: as a precaution, men and their partners should use effective contraception
- MHRA: Valproate use in men: as a precaution, men and their partners should use effective contraception
- MHRA: Valproate use in men: as a precaution, men and their partners should use effective contraception
- NHSE: Cannabis-based products for medicinal use (CBPMs)
- NHSE: Risk of death and severe harm from error with injectable phenytoin
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE evidence summary
- NICE NG217: Epilepsies in children, young people and adults
- NICE NG217: Epilepsies in children, young people and adults
- NICE NG217: Epilepsies in children, young people and adults
- NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
- NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
- NICE TA615: Cannabidiol with clobazam for treating seizures associated with LennoxGastaut syndrome
- NICE TA753: Cenobamate for treating focal onset seizures in epilepsy
- NICE TA753:Cenobamate for treating focal onset seizures in epilepsy
- NICE TA808: Fenfluramine for treating seizures associated with Dravet syndrome
- NICE TA808: Fenfluramine for treating seizures associated with Dravet syndrome
- NICE TA873 Cannabidiol for treating seizures caused by tuberous sclerosis complex
- NICE TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex
- UKMI Q&A: Why is there a limit on the dose and duration of use for carbamazepine suppositories?
- UKMI suggested drug monitoring schedule
- UKMI Suggestions for Drug Monitoring
- UKMI suggestions for drug monitoring
- UKMI suggestions for drug monitoring
UMI Q&A: Information on change of phenytoin capsules to tablets and vice versa